Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 16/20 | 0.56 |
| ▸ | RAB9A | P51151 | 16/20 | 0.56 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742755 | 0.85 | NPC1 (0.61) | TP53MAPTNPC1RAB9APAX8 | |
| SCHEMBL1744154 | 0.80 | NPC1 (0.61) | TP53MAPTNPC1RAB9APAX8 | |
| SCHEMBL3393866 | 0.78 | CHRNA7 (0.49) | TP53MAPTNPC1RAB9A | |
| SCHEMBL3391986 | 0.78 | CHRNA7 (0.49) | — | |
| SCHEMBL3391568 | 0.78 | CHRNA7 (0.49) | NPC1RAB9A | |
| SCHEMBL3390644 | 0.78 | MAOA (0.40) | TP53MAPTNPC1RAB9A | |
| SCHEMBL928191 | 0.78 | CHRNA7 (0.68) | — | |
| SCHEMBL3388713 | 0.77 | CHRNA7 (0.47) | TP53MAPTNPC1RAB9A | |
| SCHEMBL1449940 | 0.76 | GRM5 (0.45) | TP53MAPTNPC1RAB9AKMT2A | |
| SCHEMBL3389698 | 0.75 | CHRNA7 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805183-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2010-12-29 | — | — | EP | claimed |
| US-20080153806-A1 | Novel Diazabicyclic Aryl Derivatives And Their Medical Use | NEUROSEARCH A/S (DK) | 2008-06-26 | — | — | US | claimed |
| EP-1805183-B1 | NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2010-12-29 | — | — | EP | disclosed |
| US-20080153806-A1 | Novel Diazabicyclic Aryl Derivatives And Their Medical Use | NEUROSEARCH A/S (DK) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153806-A1 | Novel Diazabicyclic Aryl Derivatives And Their Medical Use | CHRNA6, CHRNA10, CHRNA2 | TP53 4839/4885MAPT 1384/4885NPC1 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.